Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 1/2016

22.09.2015 | Case Report

Methimazole Induced Total Myeloid Aplasia with Delayed Recovery Despite Granulocyte Colony Stimulating Factor (G-CSF): Marrow Progenitor Recovery Kinetics

verfasst von: Tania Sarker, Bülent Özgönenel, Manisha Gadgeel, Steven Buck, Amita Adhikari, Yaddanapudi Ravindranath

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Sonderheft 1/2016

Einloggen, um Zugang zu erhalten

Abstract

An eighteen-year-old female with Graves thyrotoxicosis presented with methimazole-induced agranulocytosis and total myeloid aplasia. The bone marrow at presentation showed complete absence of myeloid precursors and striking plasmacytosis. 16 days later, myeloid precursors were still absent morphologically; however bone marrow flow cytometry and cell culture detected an improvement in myelogenesis, which was soon followed by clinical recovery of agranulocytosis. Neutrophil recovery was delayed until day 22 after cessation of methimazole despite G-CSF use, consistent with a direct toxic effect on committed myeloid cells. Our findings suggest that cell culture and flow cytometric evaluation of bone marrow myeloid progenitors can be used as a guide to anticipate neutrophil recovery.
Literatur
1.
Zurück zum Zitat McGavack T, Chevalley J (1954) Untoward hematologic responses to the antithyroid compounds. Am J Med 17(1):36–40CrossRefPubMed McGavack T, Chevalley J (1954) Untoward hematologic responses to the antithyroid compounds. Am J Med 17(1):36–40CrossRefPubMed
2.
Zurück zum Zitat Takata K, Kubota S, Fukata S, Kudo T, Nishihara E, Ito M, Amino N, Miyauchi A (2009) Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 19(6):559–563. doi:10.1089/thy.2008.0364 CrossRefPubMed Takata K, Kubota S, Fukata S, Kudo T, Nishihara E, Ito M, Amino N, Miyauchi A (2009) Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 19(6):559–563. doi:10.​1089/​thy.​2008.​0364 CrossRefPubMed
4.
Zurück zum Zitat Cooper DS, Daniels GH, Ridgeway EC (1984) Agranulocytosis and dose of methimazole. Ann Intern Med 101(2):283CrossRefPubMed Cooper DS, Daniels GH, Ridgeway EC (1984) Agranulocytosis and dose of methimazole. Ann Intern Med 101(2):283CrossRefPubMed
5.
Zurück zum Zitat Dai WX, Zhang JD, Zhan SW, Xu BZ, Jin H, Yao Y, Xin WC, Bai Y (2002) Retrospective analysis of 18 cases of antithyroid drug (ATD)-induced agranulocytosis. Endocr J 49(1):29–33CrossRefPubMed Dai WX, Zhang JD, Zhan SW, Xu BZ, Jin H, Yao Y, Xin WC, Bai Y (2002) Retrospective analysis of 18 cases of antithyroid drug (ATD)-induced agranulocytosis. Endocr J 49(1):29–33CrossRefPubMed
9.
11.
Zurück zum Zitat Murphy MF, Chapman JF, Metcalfe P, Waters AH (1985) Antibiotic-induced neutropenia. Lancet 2(8467):1306–1307CrossRefPubMed Murphy MF, Chapman JF, Metcalfe P, Waters AH (1985) Antibiotic-induced neutropenia. Lancet 2(8467):1306–1307CrossRefPubMed
12.
Zurück zum Zitat Salama A, Schutz B, Kiefel V, Breithaupt H, Mueller-Eckhardt C (1989) Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. Br J Haematol 72(2):127–132CrossRefPubMed Salama A, Schutz B, Kiefel V, Breithaupt H, Mueller-Eckhardt C (1989) Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. Br J Haematol 72(2):127–132CrossRefPubMed
13.
Zurück zum Zitat Douer D, Eisenstein Z (1988) Methimazole-induced agranulocytosis: growth inhibition of myeloid progenitor cells by the patient’s serum. Eur J Haematol 40(1):91–94CrossRefPubMed Douer D, Eisenstein Z (1988) Methimazole-induced agranulocytosis: growth inhibition of myeloid progenitor cells by the patient’s serum. Eur J Haematol 40(1):91–94CrossRefPubMed
14.
Zurück zum Zitat Tajiri J, Noguchi S, Okamura S, Morita M, Tamaru M, Murakami N, Niho Y (1993) Granulocyte colony-stimulating factor treatment of antithyroid drug-induced granulocytopenia. Arch Intern Med 153(4):509–514CrossRefPubMed Tajiri J, Noguchi S, Okamura S, Morita M, Tamaru M, Murakami N, Niho Y (1993) Granulocyte colony-stimulating factor treatment of antithyroid drug-induced granulocytopenia. Arch Intern Med 153(4):509–514CrossRefPubMed
15.
Zurück zum Zitat Minamitani K, Oikawa J, Wataki K, Kashima K, Hoshi M, Inomata H, Ota S (2011) A report of three girls with antithyroid drug-induced agranulocytosis; retrospective analysis of 18 cases aged 15 years or younger reported between 1995 and 2009. Clin Pediatr Endocrinol 20(2):39–46. doi:10.1297/cpe.20.39 CrossRefPubMedPubMedCentral Minamitani K, Oikawa J, Wataki K, Kashima K, Hoshi M, Inomata H, Ota S (2011) A report of three girls with antithyroid drug-induced agranulocytosis; retrospective analysis of 18 cases aged 15 years or younger reported between 1995 and 2009. Clin Pediatr Endocrinol 20(2):39–46. doi:10.​1297/​cpe.​20.​39 CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Tamai H, Mukuta T, Matsubayashi S, Fukata S, Komaki G, Kuma K, Kumagai LF, Nagataki S (1993) Treatment of methimazole-induced agranulocytosis using recombinant human granulocyte colony-stimulating factor (rhG-CSF). J Clin Endocrinol Metab 77(5):1356–1360PubMed Tamai H, Mukuta T, Matsubayashi S, Fukata S, Komaki G, Kuma K, Kumagai LF, Nagataki S (1993) Treatment of methimazole-induced agranulocytosis using recombinant human granulocyte colony-stimulating factor (rhG-CSF). J Clin Endocrinol Metab 77(5):1356–1360PubMed
20.
Zurück zum Zitat Stuijver DJ, van Zaane B, Romualdi E, Brandjes DP, Gerdes VE, Squizzato A (2012) The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis. Thromb Haemost 108(6):1077–1088. doi:10.1160/TH12-07-0496 CrossRefPubMed Stuijver DJ, van Zaane B, Romualdi E, Brandjes DP, Gerdes VE, Squizzato A (2012) The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis. Thromb Haemost 108(6):1077–1088. doi:10.​1160/​TH12-07-0496 CrossRefPubMed
23.
Zurück zum Zitat Yang J, Zhong J, Xiao XH, Zhou LZ, Chen YJ, Liu JH, Cao RX, Wen GB (2013) The relationship between bone marrow characteristics and the clinical prognosis of antithyroid drug-induced agranulocytosis. Endocr J 60(2):185–189CrossRefPubMed Yang J, Zhong J, Xiao XH, Zhou LZ, Chen YJ, Liu JH, Cao RX, Wen GB (2013) The relationship between bone marrow characteristics and the clinical prognosis of antithyroid drug-induced agranulocytosis. Endocr J 60(2):185–189CrossRefPubMed
Metadaten
Titel
Methimazole Induced Total Myeloid Aplasia with Delayed Recovery Despite Granulocyte Colony Stimulating Factor (G-CSF): Marrow Progenitor Recovery Kinetics
verfasst von
Tania Sarker
Bülent Özgönenel
Manisha Gadgeel
Steven Buck
Amita Adhikari
Yaddanapudi Ravindranath
Publikationsdatum
22.09.2015
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe Sonderheft 1/2016
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-015-0595-1

Weitere Artikel der Sonderheft 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.